摘要
对2016年3月~12月入住我院重症监护室使用并监测万古霉素血清谷浓度且肌酐清除率大于120 m L·min-1的患者的一般资料、万古霉素血清浓度、疗效等临床信息进行统计分析。57例患者、96例次万古霉素血清谷浓度中,仅21.88%(21/96)达到目标浓度(15~20 mg·L-1),多重线性回归分析显示,肌酐清除率、给药剂量及血浆白蛋白为影响万古霉素血清谷浓度的主要因素(P<0.05),万古霉素达标者与未达标者病死率比较差异无统计学意义(P>0.05)。高肌酐清除率重症患者万古霉素血清谷浓度临床达标率低,需密切监测血药浓度,及时调整治疗方案。
A retrospective analysis was carried out in patients with creatinine clearance rate 120 m L·min-1 for vancomycin therapeutic drug monitoring（TDM） in intensive care unit（ICU） of the our hospital from March 2016 to December 2016. The patients＇ general information, vancomycin trough concentrations,efficacy and other clinical data were analyzed retrospectively. A total of 96 vancomycin serum trough concentrations in 57 patients were enrolled, and it was found that only 21.88%（21/96） reached the target concentration（15-20 mg·L-1）, creatinine clearance rate, dose and plasma albumin were found to be correlated to serum trough concentrations by multiple linear regression analysis（P〈0.05）. There was no significant difference in mortality between patients with targeted trough serum concentrations and those without（P〈0.05）. The rate of vancomycin serum trough concentrations reaching the standard is low in critical patients with high creatinine clearance rate, so constant monitoring and timely adjustment of treatment program is necessary.
出处
《药学与临床研究》
2017年第6期493-496,共4页
Pharmaceutical and Clinical Research
关键词
重症患者
高肌酐清除率
万古霉素
血清谷浓度
Critical patient
High creatinine clearance rate
Vancomycin
Trough oncentration
